FLAVON

• treatment of signs and symptoms of chronic venous disease, such as pain, heavyness, night cramps, oedema and trophic changes in the lower limbs;

• treatment of symptoms related to acute haemorrhoidal disease.

Treatment of acute haemorrhoidal disease with FLAVONOIDES VIATRIS COUNCIL does not replace specific treatments for other anal disorders.

Treatment should be only in the short term.

If symptoms persist, a proctological examination should be performed and treatment modified.

• Sun exposure and prolonged standing should be avoided,.

• appropriate weight should be maintained,.

• special low weight may improve circulation in some patients.

Special care is advised if the condition worsens with treatment.

This may be due to skin inflammation, venous inflammation, subcutaneous induration, severe pain, skin ulcers or atypical symptoms, e.g. instantaneous swelling of one or both legs.

COUNCIL is not effective in reducing swelling of the lower limbs caused by heart, kidney or liver disease.

This medication contains less than 1 mmol sodium (c) (expressed as "sodium)" (existingly) is "sodium" (expressed as "c.

Pharmacotherapeutic group: vasoprotectors, capillary drugs, bioflavonoids, ATC code: C05CA53.

Mechanism of action Activity on veins FLAVONOIDES VIATRIS COUNCIL reduces venous distensibility and venous stasis.

Activity on microcirculation FLAVONOIDES VIATRIS

COUNCIL reduces capillary permeability and increases capillary resistance Pharmacodynamic effects Effects on venous tone FLAVONOIDES VIATRIS COUNCIL enhances venous tone and therefore reduces blood capacity, distensibility and stasis: venous mercurial plethysmography indicates a reduction in vein emptying time Effects on the lymphatic system FLAVONOIDES VIATRIS COUNCIL stimulates lymphatic activity, improves drainage of interstitial space and increases lymphatic flow Effects on double-blind controlled clinical studies demonstrate a statistically significant difference in the clinical insighted disease and insensitized clinical insitutes of the clinical insitute.

In patients, in clinical insitivities increases the clinical insitary insitary insupresupresupment.

Most adverse reactions reported in clinical trials were mild and transient in nature, primarily related to gastrointestinal disorders (diarrhoea, dyspepsia, nausea, vomiting).

System (≥ 1/100, < 1/10) Uncommon (≥ 1/1,000, < 1/100) Rare (≥ 1/10,000, < 1/1,000) Not known (cannot be estimated from available data) Nervous system disorders Headache, malaise, dizziness Gastrointestinal disorders Diarrhoea, dyspepsia, nausea, vomiting Collitis Abdominal pain Skin and subcutaneous tissue disorders Pruritus, rash, urticaria Face, lip and eye oedema, angioedema (in exceptional cases) Reporting suspected adverse reactions Reporting suspected adverse reactions following authorization of the drug is important, allowing for ongoing monitoring of the benefit/risk ratio of the drug.

Health care professionals report suspected adverse reactions and eyelids via the national health system.